Literature DB >> 16527230

The relationship of optic disk cupping to retinal vein occlusion: the Beaver Dam Eye Study.

Barbara E K Klein1, Stacy M Meuer, Michael D Knudtson, Ronald Klein.   

Abstract

PURPOSE: To examine the association between optic disk cupping and retinal vein occlusion (RVO).
DESIGN: Prospective epidemiologic study.
METHODS: setting: Population-based prospective study in Beaver Dam, Wisconsin. study population: Adults aged 43 to 86 years at baseline (n = 4926). observation procedures: Optic disk cupping and RVO were determined from retinal photographs. A standardized medical examination and questionnaire were administered. main outcome measure: Ten-year cumulative incidence of RVO.
RESULTS: There were 58 persons who developed incident RVO at 5 (n = 31) or 10 (n = 27) years after the baseline examination. Those sustaining RVO were older, had higher intraocular pressure (IOP), and were more likely to have definite or probable glaucoma at the baseline examination. The odds of having an incident RVO increased with increasing cup-to-disk ratio at baseline (odds ratio [OR] = 1.29/0.1 increase in cup-to-disk ratio, 95% confidence interval 1.07, 1.56), while controlling for age, systolic blood pressure, current smoking, diabetes status, and IOP. A similar OR was found after excluding those with glaucoma. Excluding persons with central (as opposed to branch) vein occlusion did not have a significant effect on the OR.
CONCLUSION: Cup-to-disk ratio is a significant predictor of risk of incident RVO.

Entities:  

Mesh:

Year:  2006        PMID: 16527230     DOI: 10.1016/j.ajo.2005.12.015

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  17 in total

1.  Cup to disc ratio by optical coherence tomography is abnormal in multiple sclerosis.

Authors:  S B Syc; C V Warner; S Saidha; S K Farrell; A Conger; E R Bisker; J Wilson; T C Frohman; E M Frohman; L J Balcer; P A Calabresi
Journal:  J Neurol Sci       Date:  2011-01-11       Impact factor: 3.181

2.  Evaluation of lamina cribrosa thickness in patients diagnosed with central retinal vein occlusion.

Authors:  Orhan Altunel; Mustafa Atas; Süleyman Demircan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-03       Impact factor: 3.117

3.  Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion.

Authors:  Hai-Feng Qin; Fan-Jun Shi; Chao-Yang Zhang; Da-Wei Luo; Shi-Yue Qin; Jing Wu; Hai Xie; Jing-Ting Zhang; Qing-Hua Qiu; Kun Liu; Guo-Tong Xu; Guo-Xu Xu; Jing-Fa Zhang
Journal:  Int J Ophthalmol       Date:  2022-08-18       Impact factor: 1.645

Review 4.  Clinical implications of retinal oximetry in retinal vein occlusion: a review.

Authors:  Aditya V Belamkar; Sayena Jabbehdari; Alon Harris; Amir R Hajrasouliha
Journal:  Acta Ophthalmol       Date:  2021-11-29       Impact factor: 3.988

5.  Retinal vein occlusion: pathophysiology and treatment options.

Authors:  Niral Karia
Journal:  Clin Ophthalmol       Date:  2010-07-30

6.  Disc hemorrhages in patients with both normal tension glaucoma and branch retinal vein occlusion in different eyes.

Authors:  Young Cheol Yoo; Ki Ho Park
Journal:  Korean J Ophthalmol       Date:  2007-12

Review 7.  Neovascular Glaucoma.

Authors:  Shane J Havens; Vikas Gulati
Journal:  Dev Ophthalmol       Date:  2015-10-26

8.  The incidence of retinal vein occlusion in the ocular hypertension treatment study.

Authors:  Edward M Barnett; Aldo Fantin; Bradley S Wilson; Michael A Kass; Mae O Gordon
Journal:  Ophthalmology       Date:  2010-01-19       Impact factor: 12.079

Review 9.  Retinal vascular occlusions.

Authors:  Ingrid U Scott; Peter A Campochiaro; Nancy J Newman; Valérie Biousse
Journal:  Lancet       Date:  2020-12-12       Impact factor: 202.731

10.  Comparison between glaucomatous and non-glaucomatous eyes with unilateral retinal vein occlusion in the fellow eye.

Authors:  Soa Kim; Kyung Rim Sung; Soo Geun Joe; Jee Taek Kim; Dong Hoon Lee; Joo Yong Lee; June-Gone Kim
Journal:  Korean J Ophthalmol       Date:  2013-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.